This Plain Language Summary of Publication article (PLSP) from Future Oncology covers the DESTINY-CRC02 study, which evaluated trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic colorectal cancer that was inoperable. The results presented are from the main planned analysis, though the study was still ongoing at the time of publication.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial’ and was published in The Lancet Oncology.

Visit The Lancet using the link to read the original article.